Odyssey Therapeutics, Inc.
ODTX · Nasdaq · USD · Market cap $878M · 100 employees
Odyssey Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines for autoimmune and inflammatory diseases.
FAIL · Does not pass the screenPrice as of 20 Nov 2026Daily close, not a live quote
Screened 2026-11-20 · the tape above runs as of 12:17 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Key facts today
- Price16.96 USD at the 20 Nov 2026 close
- Fair valueUnder review: our model's value is 2.06x the price, above our 2.00x limit.
- Our regime readAccumulation, as of 15 Nov 2026
- Ethical screenDoes not pass
- Last reviewed20 Nov 2026 (1 day ago)
- Release timesRelease and earnings times on your chart: Event Guard Mentor
A summary of the dated readings below, not a live quote and not advice.
Our fair-value range: range not available (screen dated 2026-11-20).
- Trend Accumulation
- Insiders no filings inside 60 days, left as found
- Positioning no disclosures inside 60 days, left as found
- Options no verdict drawn today, left as found
- Ethical does not pass the values gate
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
This name holds its accumulation label.
Odyssey Therapeutics, Inc. holds its Accumulation at $16.96. Consolidating, no directional conviction, held for 1 days.
| Phase | Accumulation |
| Quantitative state | Consolidating, no directional conviction, held for 1 days |
| Price at the screen | $16.96 |
| Valuation | N/A trailing · -4.40 forward price to earnings |
| Values screen | FAIL · score 70.0 |
Five Screens: ODTX's Results
FAIL. Revenue purity
| Test | Figure | Limit | Status |
|---|---|---|---|
| Business activity | Permissible | Permissible core business | Pass |
| Debt load | 10.05% | Below 33% | Pass |
| Interest-bearing cash | 13.05% | Below 33% | Pass |
| Receivables | 15.45% | Below 49% | Pass |
| Revenue purity | 100.00% | Below 5% | Fail |
Definitions, sources and threshold rules: ticker values-screen methodology.
The Ethical ReadWhy It Falls Short, in Plain English
Odyssey Therapeutics, clears the business-activity screen, and its debt is inside the line. Where it falls short is income purity: around 100% of its income right now is interest earned on a large cash position, against a roughly 5% ceiling, so it does not pass. That reflects what it earns today, not the business itself, and it could clear the screen if its operating revenue grows and the interest share falls.
Read as at 20 Nov 2026. It updates when the underlying figures move, and past reads are kept below. How we screen.
Follow this verdict
Get an email when ODTX's ethical verdict changes
Today ODTX does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
The Fair Value Range
Fair value under review. Our model's value is 2.06x the price, above our 2.00x limit. We show no fair value, margin of safety or value read built on it until the review clears.
The Street's RangeStreet: 6 covering, consensus Strong Buy. Average target +106%.
| Forward P/E | -4.4x |
| EPS, trailing | -7.55 |
| EPS, forward | -4.15 |
| Profit margin | 0.0%currently unprofitable |
| Debt to equity | 0.06minimal debt: a conservative balance sheet |
| Current ratio | 11.36comfortably covers its short-term bills |
| Short interest, float | 0.07% |
| 52-week range | 15.10 - 29.05 |
| Market cap | $878M |
| Employees | 100 |
ODTX-specific watchpoints · The things to watch: it's a small-cap, so the share price can swing harder than the market; as a biotechnology name, trial and regulatory outcomes can move it sharply either way.
Metric definitions and interpretation rules: ticker-page methodology.
Every Entry, As Written
The framework has shifted from markdown to accumulation since the last review.
Earnings landed in this window. Ethical screening: FAIL.
Written on its date, before the outcome; never pruned.
Screened names in the same industry · explore each on its own page.
| Period | Price then | Price return | Divs per share | $1,000 became | Total return |
|---|---|---|---|---|---|
| 1 month | $17.45 | -6.9% | · | $932 | -6.9% |
Historical returns from market close data. Past performance does not guarantee future results.
This entry now belongs to the ledger. Whatever ODTX does next, these words stay.
Thirteen thousand names carry this page. One desk keeps them honest.
Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.
Join the deskScreening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.